8-K: Globus Medical Reports Record Q4, Full Year 2025 Sales

Globus Medical announced preliminary record fourth quarter and full year 2025 sales, along with robust 2026 financial guidance.

Summary

• Preliminary unaudited net sales for the fourth quarter ended December 31, 2025, are approximately $823.2 million, marking a 25.2% increase over the fourth quarter of 2024.
• Preliminary unaudited full year 2025 sales are expected to be approximately $2.936 billion, an increase of 16.5% over the prior year.
• The company established full year 2026 revenue guidance in the range of $3.18 billion to $3.22 billion.
• Preliminary guidance for fully diluted non-GAAP earnings per share for fiscal year 2026 is between $4.30 and $4.40.
• Excluding the impact of Nevro sales, total Globus base business revenue for Q4 2025 was $723.3 million, a 10.0% increase over the prior year fourth quarter, driven by the US Spine business.
• Enabling Technologies delivered its best quarterly revenue performance to date in Q4 2025.

Sentiment

Score: 8

Explanation: The filing reports record preliminary sales for Q4 and full year 2025, significant growth rates, successful integration of acquisitions, and strong 2026 guidance, all indicating very positive operational performance and future outlook. The language used by management is also highly optimistic.

Positives

• Achieved preliminary record sales for both the fourth quarter and full year 2025.
• Reported strong Q4 2025 sales growth of 25.2% and full year 2025 sales growth of 16.5% on an as-reported basis.
• Demonstrated continued growth and market share gains within the US Spine business.
• Enabling Technologies segment recorded its best quarterly revenue performance ever.
• Successfully integrated the NuVasive and Nevro acquisitions, contributing to overall growth.
• Base business revenue, excluding Nevro, grew by 10.0% in Q4 2025, indicating strong organic performance.
• Provided optimistic 2026 guidance, aiming for above-market growth and shareholder value generation.

Risks

• Risks and costs associated with health epidemics, pandemics, and similar outbreaks.
• Factors that could affect quarterly results.
• Ability to manage growth and sustain profitability.
• Demand for products.
• Ability to compete successfully, including convincing surgeons to use products and attracting and retaining sales and other personnel.
• Ability to rapidly develop and introduce new products.
• Ability to develop and execute successful business strategies.
• Ability to comply with laws and regulations that are or may become applicable to businesses.
• Ability to safeguard intellectual property.
• Success in defending legal proceedings brought against the company.
• Trends in the medical device industry.
• General economic conditions.
• Successful integration of businesses that have been acquired or may be acquired in the future.
• New risk factors and uncertainties may emerge, and it is not possible to predict all of them or assess their full impact.

Future Outlook

The company looks to 2026 with confidence, aiming to build upon the successes of the past year by driving above-market growth and generating value for shareholders. The strategic focus includes driving innovation, operational excellence, introducing a robust pipeline of new products, maintaining disciplined investment, and executing a strategy of sustained, profitable growth.

Management Comments

• "We're thrilled with our preliminary Q4 results, capping off a strong finish to 2025." Keith Pfeil, President and CEO.
• "Globus closed 2025 with strong momentum, delivering meaningful revenue growth across the business, while advancing operational priorities and integrating the Nevro acquisition." Keith Pfeil, President and CEO.
• "Fourth quarter results reflected the continued trend of growth and market share gains within US Spine, while Enabling Technologies delivered its best quarterly revenue performance to date." Keith Pfeil, President and CEO.
• "Our fourth quarter results demonstrated above market growth as well as continued success in the integration of the NuVasive and Nevro acquisitions." Kyle Kline, CFO.
• "Looking ahead to 2026, we aim to build upon the successes of the past year, as we drive above market growth and generate value for our shareholders." Kyle Kline, CFO.

Industry Context

Globus Medical operates in the dynamic musculoskeletal solutions and medical device industry. The reported preliminary record sales and significant growth rates, particularly in US Spine and Enabling Technologies, suggest the company is effectively capturing market share and executing its strategy within a competitive landscape. The successful integration of recent acquisitions (NuVasive and Nevro) positions the company for continued expansion, aligning with broader industry trends of consolidation and technological advancement to address musculoskeletal disorders.

Comparison to Industry Standards

• Reported "above market growth" in the fourth quarter, indicating outperformance relative to the broader medical device industry.
• No specific comparable companies, projects, or results were detailed for direct benchmarking within the filing.

Stakeholder Impact

• Shareholders: Likely positive impact due to strong financial performance, record sales, successful acquisition integration, and optimistic 2026 guidance, potentially leading to increased shareholder value.
• Employees: Continued focus on growth and operational excellence may imply stability and opportunities, especially with successful integration of acquired entities.
• Customers: Innovation and new product pipeline suggest continued development of solutions for musculoskeletal disorders.
• Suppliers: Increased sales and production may lead to increased demand for supplier services/products.

Next Steps

• Announce final fourth quarter and full year 2025 financial results on February 24, 2026, after the market close.
• Continue to drive innovation and operational excellence in 2026.
• Introduce a robust pipeline of new products.
• Maintain disciplined investment.
• Execute the strategy of sustained, profitable growth.

Key Dates

Recommendation

The filing presents exceptionally strong preliminary financial results, including record sales and significant growth rates well above market averages. The successful integration of major acquisitions (NuVasive and Nevro) and robust 2026 guidance for both revenue and non-GAAP EPS demonstrate strong operational execution and a positive future outlook. The company's focus on innovation and market share gains in key segments like US Spine and Enabling Technologies further solidifies its competitive position. These factors collectively suggest a compelling investment opportunity with strong upside potential.

Keywords

Globus Medical, GMED, Q4 2025 sales, full year 2025 sales, 2026 guidance, revenue, earnings per share, musculoskeletal solutions, medical devices, US Spine, Enabling Technologies, NuVasive, Nevro, acquisitions